BIOMAT Database Logo BIOMAT Database Logo

Bioavailability of pyridoxal phosphate from enteric-coated tablets. I. Apparent critical dissolution pH and bioavailability of commercial products in humans. 1985

N Kaniwa, and H Ogata, and N Aoyagi, and M Koibuchi, and T Shibazaki, and A Ejima, and S Takanashi, and H Kamiyama, and H Suzuki, and Y Hinohara

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011732 Pyridoxal Phosphate This is the active form of VITAMIN B 6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is transiently converted into pyridoxamine phosphate (PYRIDOXAMINE). Pyridoxal 5-Phosphate,Pyridoxal-P,Phosphate, Pyridoxal,Pyridoxal 5 Phosphate,Pyridoxal P
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006863 Hydrogen-Ion Concentration The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH pH,Concentration, Hydrogen-Ion,Concentrations, Hydrogen-Ion,Hydrogen Ion Concentration,Hydrogen-Ion Concentrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities
D013608 Tablets, Enteric-Coated Tablets coated with material that delays release of the medication until after they leave the stomach. (Dorland, 28th ed) Enteric-Coated Tablets,Tablets, Enteric Coated

Related Publications

N Kaniwa, and H Ogata, and N Aoyagi, and M Koibuchi, and T Shibazaki, and A Ejima, and S Takanashi, and H Kamiyama, and H Suzuki, and Y Hinohara
Dissolution behavior of commercial enteric-coated aspirin tablets.
October 1979, Journal of pharmaceutical sciences,
N Kaniwa, and H Ogata, and N Aoyagi, and M Koibuchi, and T Shibazaki, and A Ejima, and S Takanashi, and H Kamiyama, and H Suzuki, and Y Hinohara
[Bioavailability and dissolution test of commercial carbamazepine tablets].
January 1984, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
N Kaniwa, and H Ogata, and N Aoyagi, and M Koibuchi, and T Shibazaki, and A Ejima, and S Takanashi, and H Kamiyama, and H Suzuki, and Y Hinohara
[Influence of formulation of enteric coated tablets on the bioavailability of the drug. 4th Part: Influence of the enteric polymer dissolution pH on the "in vivo" absorption of aspirin from coated tablets (author's transl)].
January 1976, Journal de pharmacie de Belgique,
N Kaniwa, and H Ogata, and N Aoyagi, and M Koibuchi, and T Shibazaki, and A Ejima, and S Takanashi, and H Kamiyama, and H Suzuki, and Y Hinohara
Bioavailability and dissolution properties of two commercial digoxin tablets.
August 1974, Journal of pharmaceutical sciences,
N Kaniwa, and H Ogata, and N Aoyagi, and M Koibuchi, and T Shibazaki, and A Ejima, and S Takanashi, and H Kamiyama, and H Suzuki, and Y Hinohara
[Influence of formulation of enteric coated tablets on the bioavailability of the drug. 5th Part: Bioavailability of Riboflavin enteric coated tablets (author's transl)].
January 1976, Journal de pharmacie de Belgique,
N Kaniwa, and H Ogata, and N Aoyagi, and M Koibuchi, and T Shibazaki, and A Ejima, and S Takanashi, and H Kamiyama, and H Suzuki, and Y Hinohara
pH-dependent dissolution rate of nitrofurantoin from commercial suspensions, tablets, and capsules.
April 1974, Journal of pharmaceutical sciences,
N Kaniwa, and H Ogata, and N Aoyagi, and M Koibuchi, and T Shibazaki, and A Ejima, and S Takanashi, and H Kamiyama, and H Suzuki, and Y Hinohara
Absolute bioavailability of fluoride from disodium monofluorophosphate and enteric-coated sodium fluoride tablets.
January 1996, European journal of clinical pharmacology,
N Kaniwa, and H Ogata, and N Aoyagi, and M Koibuchi, and T Shibazaki, and A Ejima, and S Takanashi, and H Kamiyama, and H Suzuki, and Y Hinohara
[Bioavailability of commercial chloramphenicol tablets in humans (author's transl)].
May 1975, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
N Kaniwa, and H Ogata, and N Aoyagi, and M Koibuchi, and T Shibazaki, and A Ejima, and S Takanashi, and H Kamiyama, and H Suzuki, and Y Hinohara
[Effect of dissolving pH of enteric coating agent on bioavailability of enteric coated tablets of erythromycin in man (author's transl)].
August 1978, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
N Kaniwa, and H Ogata, and N Aoyagi, and M Koibuchi, and T Shibazaki, and A Ejima, and S Takanashi, and H Kamiyama, and H Suzuki, and Y Hinohara
Effect of cimetidine on bioavailability of enteric-coated aspirin tablets.
January 1983, Clinical pharmacy,
Copied contents to your clipboard!